John G. Compton - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Role
Director
Signature
/s/ John G. Compton
Issuer symbol
N/A
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
3
Filing time
17 Feb 2026, 18:28:25 UTC
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Compton John G. Director C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG /s/ John G. Compton 17 Feb 2026 0002107487

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding Common Stock 6,666 17 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding Series A-2 Preferred Stock 17 Feb 2026 Common Stock 7,669 Direct F1
holding Stock Option 17 Feb 2026 Common Stock 48,780 $0.8200 Direct F2
holding Stock Option 17 Feb 2026 Common Stock 76,628 $1.04 Direct F3
holding Stock Option 17 Feb 2026 Common Stock 37,584 $1.06 Direct F4
holding Stock Option 17 Feb 2026 Common Stock 37,583 $1.06 Direct F5
holding Stock Option 17 Feb 2026 Common Stock 30,000 $1.74 Direct F6
holding Stock Option 17 Feb 2026 Common Stock 30,000 $2.55 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.
F2 On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.
F3 On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.
F4 On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.
F5 On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.
F6 On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.
F7 On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.